BioDelivery Sciences risk/reward profile favorable, says William Blair William Blair reiterates an Outperform rating on shares of BioDelivery Sciences ahead of the June 7 PDUFA date for Bunavail, the company's buprenorphine/naloxone sublingual film for the treatment of opioid addiction. The firm says the FDA has been focused on new therapies for opioid addiction given the current opioid-abuse crisis. It views the risk/reward for BioDelivery shares as favorable and has a $16 price target for the stock.
Summer Street still feels Endo could acquire BioDelivery Sciences Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.